A clinical trial of canakinumab (a neutralizing antibody against IL-1β) observed a reduction in the rate of cardiovascular events in patients with CKD without modifying renal function, which is clinically relevant, as few therapies have been shown to be effective in reducing the likelihood of cardiovascular events in patients with kidney disease. This evidence concerns the gene IL1B and chronic kidney disease.